[go: up one dir, main page]

MX2017004378A - Formulaciones farmaceuticas de liposomas pegilados y factores de coagulacion sanguinea. - Google Patents

Formulaciones farmaceuticas de liposomas pegilados y factores de coagulacion sanguinea.

Info

Publication number
MX2017004378A
MX2017004378A MX2017004378A MX2017004378A MX2017004378A MX 2017004378 A MX2017004378 A MX 2017004378A MX 2017004378 A MX2017004378 A MX 2017004378A MX 2017004378 A MX2017004378 A MX 2017004378A MX 2017004378 A MX2017004378 A MX 2017004378A
Authority
MX
Mexico
Prior art keywords
pegilated
liposomes
pharmaceutical formulations
blood coagulation
coagulation factors
Prior art date
Application number
MX2017004378A
Other languages
English (en)
Other versions
MX384517B (es
Inventor
Henry William
Original Assignee
Cantab Biopharmaceuticals Patents Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cantab Biopharmaceuticals Patents Ltd filed Critical Cantab Biopharmaceuticals Patents Ltd
Publication of MX2017004378A publication Critical patent/MX2017004378A/es
Publication of MX384517B publication Critical patent/MX384517B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4833—Thrombin (3.4.21.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4866—Protein C (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A61K9/1278—Post-loading, e.g. by ion or pH gradient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención proporciona una composición farmacéutica para administración subcutánea, que comprende un factor sanguíneo y una partícula coloide que comprende aproximadamente entre un 0.5 y un 20 por ciento en moles de un lípido anfipático derivatizado con un polímero hidrófilo biocompatible, donde el factor sanguíneo no está encapsulado en dicha partícula coloide.
MX2017004378A 2014-10-06 2015-10-06 Formulaciones farmaceuticas de liposomas pegilados y factores de coagulacion sanguinea. MX384517B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1417589.7A GB201417589D0 (en) 2014-10-06 2014-10-06 Pharmaceutical Formulations
PCT/EP2015/073003 WO2016055447A1 (en) 2014-10-06 2015-10-06 Pharmaceutical formulations of pegylated liposomes and blood coagulation factors

Publications (2)

Publication Number Publication Date
MX2017004378A true MX2017004378A (es) 2018-02-09
MX384517B MX384517B (es) 2025-03-14

Family

ID=51946871

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017004378A MX384517B (es) 2014-10-06 2015-10-06 Formulaciones farmaceuticas de liposomas pegilados y factores de coagulacion sanguinea.

Country Status (16)

Country Link
US (2) US20170304203A1 (es)
EP (1) EP3204034B9 (es)
JP (3) JP2017531659A (es)
AU (1) AU2015330102B2 (es)
BR (1) BR112017007031A2 (es)
CA (1) CA2994891C (es)
ES (1) ES2954134T3 (es)
GB (1) GB201417589D0 (es)
HR (1) HRP20230985T1 (es)
HU (1) HUE063656T2 (es)
MX (1) MX384517B (es)
PL (1) PL3204034T3 (es)
RS (1) RS64461B1 (es)
RU (1) RU2737291C2 (es)
SM (1) SMT202300271T1 (es)
WO (1) WO2016055447A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201417589D0 (en) * 2014-10-06 2014-11-19 Cantab Biopharmaceuticals Patents Ltd Pharmaceutical Formulations
CN109069425B (zh) * 2016-05-26 2021-07-30 贝克顿·迪金森公司 用于通过离心制备脂质体的方法和装置

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US6326353B1 (en) 1993-03-23 2001-12-04 Sequus Pharmaceuticals, Inc. Enhanced circulation effector composition and method
ATE179599T1 (de) 1993-08-06 1999-05-15 Opperbas Holding Bv Verfahren zur hohen beladung von vesikeln mit biopolymeren substanzen
IL113010A0 (en) * 1994-03-31 1995-10-31 Pharmacia Ab Pharmaceutical formulation comprising factor VIII or factor ix with an activity of at least 200 IU/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration
US6156337A (en) * 1994-07-08 2000-12-05 Opperbas Holding B.V. Method for high loading of vesicles with biopolymeric substances
WO2001082943A2 (en) * 2000-05-03 2001-11-08 Novo Nordisk A/S Subcutaneous administration of coagulation factor vii
US6310183B1 (en) * 1997-09-10 2001-10-30 Novo Nordisk A/S Coagulation factor VIIa composition
PT1079805E (pt) 1998-04-27 2005-03-31 Opperbas Holding Bv Composicao farmaceutica compreendendo factor viii e lipossomas neutros
KR20070086708A (ko) 1999-07-14 2007-08-27 알자 코포레이션 중성 지질중합체 및 그를 함유하는 리포솜 조성물
US20030232075A1 (en) 2002-05-06 2003-12-18 University Of Minnesota, A Minnesota Corporation Compositions for producing factor Xa
DK1633440T3 (da) 2003-04-15 2008-09-08 Opperbas Holding Bv Farmaceutisk sammensætning omfattende proteiner og/eller polypeptider og kolloidale partikler
AU2006263566A1 (en) 2005-06-29 2007-01-04 The Research Foundation Of State Of University Of New York At Buffalo Compositions and methods for less immunogenic protein-lip1d complexes
EP2099475B1 (en) * 2007-01-03 2016-08-24 Novo Nordisk Health Care AG Subcutaneous administration of coagulation factor viia-related polypeptides
US20090117087A1 (en) 2007-04-13 2009-05-07 Wake Forest University Methods and compositions for printing biologically compatible nanotube composites of autologous tissue
CN105434353A (zh) 2009-06-03 2016-03-30 斯昆申技术控股有限责任公司 用于治疗深部组织疼痛的制剂
DE112010003355T5 (de) 2009-08-21 2012-07-12 Targeted Delivery Technologies Ltd. Veskuläre Formulierungen
GB201007357D0 (en) 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIII
GB201007356D0 (en) * 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIIa
AR082803A1 (es) * 2010-09-01 2013-01-09 Portola Pharm Inc Metodos y formulaciones para el tratamiento de la trombosis con betrixaban y un inhibidor de la glicoproteina p
MY190257A (en) * 2012-04-16 2022-04-11 Cantab Biopharmaceuticals Patents Ltd Optimised subcutaneous therapeutic agents
GB201417589D0 (en) * 2014-10-06 2014-11-19 Cantab Biopharmaceuticals Patents Ltd Pharmaceutical Formulations

Also Published As

Publication number Publication date
CA2994891C (en) 2023-04-04
EP3204034B1 (en) 2023-06-07
HUE063656T2 (hu) 2024-01-28
JP7573582B2 (ja) 2024-10-25
WO2016055447A1 (en) 2016-04-14
RS64461B1 (sr) 2023-09-29
BR112017007031A2 (pt) 2018-01-30
EP3204034B9 (en) 2023-10-04
CA2994891A1 (en) 2016-04-14
EP3204034C0 (en) 2023-06-07
AU2015330102B2 (en) 2021-01-28
PL3204034T3 (pl) 2023-11-06
RU2017115831A (ru) 2018-11-14
RU2737291C2 (ru) 2020-11-26
MX384517B (es) 2025-03-14
ES2954134T3 (es) 2023-11-20
AU2015330102A1 (en) 2017-05-25
SMT202300271T1 (it) 2023-09-06
JP2017531659A (ja) 2017-10-26
GB201417589D0 (en) 2014-11-19
RU2017115831A3 (es) 2019-05-06
EP3204034A1 (en) 2017-08-16
JP2023002687A (ja) 2023-01-10
JP2020183446A (ja) 2020-11-12
US20170304203A1 (en) 2017-10-26
US11484499B2 (en) 2022-11-01
HRP20230985T1 (hr) 2023-12-08
US20190060235A1 (en) 2019-02-28

Similar Documents

Publication Publication Date Title
CO2018003424A2 (es) Composición farmacéutica y formulación de inyección subcutánea que comprende micelas y curcuminoides para reducir la grasa localizada y método para preparar la misma”
CL2009001856A1 (es) Suspension farmaceutica submicronica que comprende el agente terapeutico nepafenac, un polimero cargado de bajo peso molecular y uno o mas excipientes; metodo de preparacion, util para administrar ocularmente.
MX384021B (es) Composiciones y metodos para aplicaciones oftalmicas y/u otras aplicaciones.
AR090491A1 (es) Tratamiento de la esclerosis multiple con una combinacion de laquinimod y fumarato de dimetilo
MX2018001723A (es) Conjugados farmaco-multiligando y usos de los mismos.
CY1122899T1 (el) Υδατικη συσταση περιλαμβανουσα παρακεταμολη και ιβουπροφαινη
ECSP15004752A (es) Formulaciones de etanercept que muestran una marcada reducción de la cantidad de partículas subvisibles
MX2016005232A (es) Formulaciones liposomicas para inhalacion, modificadas con agente tensoactivo, que proveen un perfil de liberacion tanto inmediata como sostenida.
AR088585A1 (es) Un medicamento para tratar la enfermedad del ojo anterior
BR112015023481A2 (pt) composição de lipossoma de liberação controlada de fármaco
AR096402A1 (es) Medicamento de metformina y dihidroquercetina
BR112018015367A2 (pt) carreadores oromucosais de nanofibra para tratamento terapêutico
PH12015502556A1 (en) Modified release formulation
MX2016009217A (es) Inmunoterapia basada en liposomas.
ES2659519T3 (es) Método para producir medicamentos para combatir tumores
CL2012002781A1 (es) Producto que comprende un cuerpo de alimento compuesto por un componente de alimento y un componente de infusion que contiene mal todextrina en una concentracon de 5 a 65% con respecto al cuerpo del alimento; producto alimenticio; metodo para producir un cuerpo de alimento infusionado; y formulaciones de infusion.
AR102778A1 (es) Composición farmacéutica, su preparación y sus usos
ES2616035T3 (es) Preparación para su uso en la profilaxis y el tratamiento de osteoporosis atípica
MX2018004445A (es) Particulas coloidales para su uso en medicina.
BR112018010066A8 (pt) Agente estimulante do receptor 5-hidroxitriptamina 1b para intensificar potencial de enxerto in vivo
MX2017004378A (es) Formulaciones farmaceuticas de liposomas pegilados y factores de coagulacion sanguinea.
UY31790A (es) Utilización de dronedarona para preparar un medicamento para el tratamiento de pacientes con arritmia y que tienen un incremento del nivel de creatinina debido a la administración de dronedarona
CL2012003209A1 (es) Metodo de sintesis de nanoparticulas de acido poli (lactico-glicolico) (plga) con pentoxifilina; composicion farmaceutica que comprende nanoparticulas de plga con pentoxifilina; y uso de las nanoparticulas de plga cargada con pentoxifilina en el tratamiento del alivio y prevencion del dolor cronico.
MX388310B (es) Formulaciones nanoestructuradas para el suministro de silibinina y otros ingredientes activos para tratar enfermedades oculares
GB201204632D0 (en) Delivery system